BioSpace News Archive

Mozart Therapeutics , a leading developer of CD8 Treg modulators in autoimmune and inflammatory disease, today announced it will present at Digestive Disease Week ® (DDW) taking place May 21-24, 2022 in San Diego, CA and virtually.

Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) is pleased to announce that its CEO, Dr. Roger McIntyre has been invited to speak at the American Psychiatric Association Annual Meeting in New Orleans May 21, 2022.

Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at H.C. Wainwright’s upcoming Annual Global Investment Conference.

AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, provided an update on its ongoing efforts to develop an effective therapeutic for “Long COVID” with its investigational drug, Ampligen.

Applied Genetic Technologies Corporation announced that Sue Washer, President & Chief Executive Officer, Jon Lieber, Chief Financial Officer, and Susan Schneider, Chief Medical Officer, will be presenting virtually at the H.C. Wainwright Global Investment Conference held May 23 - 26, 2022.

BioSyent Inc. released its financial results for the three months ended March 31, 2022.

Oncotelic Therapeutics, Inc. announced the Company will be presenting at the BIO International Convention taking place in San Diego, California between June 13 - 16, 2022.

iCAD, Inc. announced that new research supporting ProFound AI® for Digital Breast Tomosynthesis will be presented at the Society of Breast Imaging Breast Imaging Symposium, taking place May 16-19 in Savannah, GA.

BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”) has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company’s autologous haptenized tumor cell vaccine for late-stage ovarian cancer.